PERSPECTIVE THERAPEUTICS, INC. Total Long-Term Debt
PERSPECTIVE THERAPEUTICS, INC. (CATX) had Total Long-Term Debt of $1.60 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-08-10
- 2026-06-30: Long-term Debt $1.60M.
- 2026-03-31: Long-term Debt $1.61M.
- 2025-12-31: Long-term Debt $1.63M.
- 2025-09-30: Long-term Debt $1.64M.
| Period end | Long-term Debt |
|---|---|
| 2026-06-30 | $1.60M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $1.61M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $1.63M 10-K · filed 2026-03-16 |
| 2025-09-30 | $1.64M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $1.65M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $1.66M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $1.68M 10-K/A · filed 2025-03-28 |
| 2024-09-30 | $1.69M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.71M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.71M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $1.73M 10-K · filed 2024-03-28 |
| 2023-09-30 | $1.74M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $1.77M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $1.79M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |